Who Is the Executive Holding Over 1 Trillion Won in Stocks? The 'Big Winners' Among Newly Listed Companies

Last year, more than 100 individual shareholders in newly listed companies on the domestic stock market had stock valuations exceeding 10 billion won. Among them, there was even an individual whose stock valuation surpassed 1 trillion won.

According to the Korea CXO Institute on January 19, among individual shareholders of the 121 companies that went public last year, 119 individuals had stock valuations exceeding 10 billion won as of the closing price on January 16.

Yonhap News Agency

Specifically, there was one individual with over 1 trillion won, 19 individuals with between 100 billion and 1 trillion won, 19 individuals with between 50 billion and 100 billion won, 14 individuals with between 30 billion and 50 billion won, and 67 individuals with between 10 billion and 30 billion won. Additionally, 101 individuals had stock valuations between 1 billion and 10 billion won.

The individual whose stock valuation exceeded 1 trillion won was Nam Dohyun, Chief Technology Officer (CTO) and largest shareholder of the pharmaceutical and biotech company AIMEDBIO. Nam holds approximately 22.16 million shares of AIMEDBIO, valued at 1.2168 trillion won. This represents an increase of about 25% compared to the company's IPO in December last year.

Those whose stock valuations exceeded 300 billion won include Lee Jeongju, CEO of Livesmed; Lee Haengmyeong, CEO of Myungin Pharmaceutical; Lee Seungju, CEO of Orum Therapeutics; Lee Seonguk, CEO of Algenomics; and Ban Seongyeon, CEO of Dalba Global.

In particular, Lee Seungju, CEO of Orum Therapeutics, saw the company's stock price soar by 458.7% after its listing, causing the value of his holdings to skyrocket from 73.8 billion won to 412.6 billion won. Some other biotech companies, such as Rokit Healthcare and Proteina, also saw their stock prices jump by more than 300% after going public.

By age group, those born in the 1960s and 1970s accounted for the largest numbers, with 38 individuals each, followed by 33 individuals born in the 1980s and 1990s. There were also 12 individuals in their 30s who became stock-rich.

Oh Ilseon, head of the Korea CXO Institute, stated, "Among the newly listed companies last year, the pharmaceutical and biotech sectors dominated the upper ranks of stock-rich individuals. However, in order to sustain the upward trend in stock prices, these companies will need to show improved performance going forward."